Article info

Download PDFPDF

Letter
Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis
Free
  1. Correspondence to Vincenzina Lucidi, Department of Pediatric Medicine, Unit of Cystic Fibrosis, Bambino Gesù Children's Hospital, P.zza S. Onofrio n. 4, 00165 Rome, Italy; vincenzina.lucidi{at}opbg.net
View Full Text

Citation

Alghisi F, Palma P, Montemitro E, et al
Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis

Publication history

  • Accepted November 25, 2010
  • First published January 12, 2011.
Online issue publication 
February 18, 2011

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.